Alkermes plc executive Craig C. Hopkinson reported equity award activity involving restricted stock units and ordinary shares. On 2/26/2026, he exercised 6,866 restricted stock units, which converted into 6,866 ordinary shares at a stated price of $0.0000 per share. In a related tax-withholding transaction, 3,049 ordinary shares were disposed of at $30.73 per share to cover tax obligations rather than as an open-market sale. Following these transactions, he directly held 93,389 ordinary shares and 13,732 restricted stock units. Each restricted stock unit represents a contingent right to receive one ordinary share and the award vests in four equal annual installments commencing on 02/26/2025.
Alkermes plc executive David Joseph Gaffin reported equity award activity. On 2/26/2026, he acquired 6,866 restricted stock units and 6,866 ordinary shares through an exercise or conversion of derivative securities. A separate transaction disposed of 3,049 ordinary shares at $30.73 per share to satisfy tax obligations.
After these transactions, Gaffin directly held 13,732 restricted stock units and 239,694 ordinary shares. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments beginning on 2/26/2025.
Alkermes plc VP Samuel Joseph Parisi reported equity award activity. On 2/23/2026, 2,283 restricted stock units were exercised or converted into 2,283 ordinary shares at a price of $0.00 per share. A separate transaction disposed of 672 ordinary shares at $32.19 per share to cover tax withholding obligations. Each restricted stock unit represents a contingent right to receive one ordinary share, and the award vests in four equal annual installments starting on 2/23/2024. After these transactions, he directly held 2,284 restricted stock units and 12,668 ordinary shares.
Alkermes plc senior vice president and chief commercial officer Christian Todd Nichols reported equity compensation activity involving restricted stock units and ordinary shares. On 2/23/2026, 6,407 restricted stock units were exercised into 6,407 ordinary shares at a price of $0.00 per share, reflecting a derivative exercise or conversion. To cover tax obligations, 2,845 ordinary shares were disposed of at $32.19 per share through a tax-withholding transaction. After these movements, Nichols directly owned 112,762 ordinary shares. Each restricted stock unit represents a right to receive one ordinary share, and units vest in four equal annual installments beginning 2/23/2024.
Alkermes plc EVP and COO Jackson Blair Curtis reported equity transactions on 2/23/2026. He exercised a restricted stock unit award, converting 8,738 restricted stock units into 8,738 ordinary shares at a stated price of $0.0000 per share.
To cover tax obligations related to this equity compensation, 3,880 ordinary shares were disposed of in a tax-withholding transaction at $32.1900 per share. After these transactions, Curtis directly owned 236,681 ordinary shares. Each restricted stock unit represents one ordinary share and vests in four equal annual installments beginning on 2/23/2024.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised 7,689 restricted stock units into ordinary shares on February 23, 2026, with each unit converting into one share. On the same date, 3,414 ordinary shares at $32.19 per share were withheld to cover tax obligations, leaving him with 89,572 ordinary shares held directly. The restricted stock unit award vests in four equal annual installments beginning on February 23, 2024.
Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported the vesting and exercise of 7,689 restricted stock units into ordinary shares on February 23, 2026. In a related tax-withholding disposition, 3,414 ordinary shares were used at $32.19 per share. Following these transactions, he directly holds 235,877 ordinary shares. The restricted stock unit award vests in four equal annual installments beginning February 23, 2024.
Alkermes plc describes a global neuroscience-focused biopharmaceutical business built around proprietary drugs for alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, plus licensed and technology-partnered products.
The company completed the acquisition of Avadel Pharmaceuticals in February 2026, adding LUMRYZ, the first once-at-bedtime sodium oxybate for narcolepsy, and a dedicated commercial organization. Alkermes highlights key products ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL, royalty-generating collaborations with Janssen and Biogen, and a late-stage pipeline led by alixorexton, an orexin 2 receptor agonist with FDA Breakthrough Therapy designation in narcolepsy. The filing also outlines extensive patent protection, manufacturing arrangements, intense competitive pressures and numerous business risks, including reliance on a few major products, regulatory and IP challenges, debt obligations and potential volatility in its ordinary shares.
Alkermes plc announced a planned CEO transition. Long‑time Chief Executive Officer Richard F. Pops will retire from the CEO role effective July 31, 2026, after about 35 years, and will remain non‑executive Chairman while serving as Senior Advisor through December 31, 2026.
Executive Vice President and Chief Operating Officer Blair C. Jackson has been appointed to become CEO effective August 1, 2026. Jackson has more than two decades at Alkermes in scientific, operational and strategic roles and previously served as interim principal financial officer.
Under a letter agreement, Pops will receive a $75,000 monthly cash retainer as Senior Advisor, a fiscal 2026 cash bonus at target level prorated for his CEO service, and a 2026 time‑based restricted stock unit award with a grant value of $2,687,500, prorated to reflect service through the Senior Advisor term and scheduled to vest on December 31, 2026. He will also receive a prorated $40,000 annual retainer for his service as non‑executive Chairman, continued vesting of existing equity awards under specified post‑service terms, and reimbursement of up to $60,000 in legal fees related to the transition.
Alkermes plc reported 2025 total revenue of $1.48 billion, down from $1.56 billion, as royalties declined after the INVEGA SUSTENNA® U.S. royalty expiry, even though proprietary net sales rose to $1.18 billion. LYBALVI® grew to $346.7 million, ARISTADA® to $370.0 million and VIVITROL® to $467.9 million.
GAAP net income for 2025 was $241.7 million, or $1.43 diluted EPS, compared with $367.1 million and $2.17 in 2024, and Adjusted EBITDA declined to $394.0 million. The company closed its Avadel acquisition, using about $775 million of cash and adding $1.525 billion of term loans, gaining LUMRYZ® and a stronger sleep-medicine franchise. For 2026, Alkermes expects revenues of $1.73–$1.84 billion, proprietary net sales driven by VIVITROL®, LYBALVI®, ARISTADA® and LUMRYZ®, but a GAAP net loss of $(115)–$(135) million and Adjusted EBITDA of $370–$410 million as it absorbs Avadel-related costs and ramps its orexin portfolio.